Nonalcoholic Fatty Liver Disease-Evidence for a Thrombophilic State?
Publication/Presentation Date
1-1-2020
Abstract
Nonalcoholic fatty liver disease is the leading cause of liver disease worldwide. It has expansive extrahepatic morbidity and mortality including increased rates of both cardiovascular disease and venous thromboembolism. Derangements in primary, secondary and tertiary hemostasis are found in nonalcoholic fatty liver disease independent of those ascribed to end-stage liver disease. The abnormalities across all stages of hemostasis explain the increased rates of clinically relevant thrombotic events, including pulmonary embolism, deep vein thrombosis and portal vein thrombosis, which on an epidemiologic basis appears to be independent of obesity and other traditional venous thromboembolic risk factors. However, given the complex interaction between obesity, body composition and nonalcoholic fatty liver disease and the potential for exercise to benefit all three, more research is needed to further define the role of each in contributing to the prohemostatic state of nonalcoholic fatty liver disease in order to improve patient oriented outcomes.
Volume
26
Issue
10
First Page
1036
Last Page
1044
ISSN
1873-4286
Published In/Presented At
Spinosa, M., & Stine, J. G. (2020). Nonalcoholic Fatty Liver Disease-Evidence for a Thrombophilic State?. Current pharmaceutical design, 26(10), 1036–1044. https://doi.org/10.2174/1381612826666200131101553
Disciplines
Medicine and Health Sciences
PubMedID
32003679
Department(s)
Department of Medicine, Department of Medicine Fellows and Residents, Fellows and Residents
Document Type
Article